文献速递淋巴瘤白血病

伊布替尼治疗经典型与变异型毛细胞白血病的2期研究

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
PubMed 文献 · Blood · 2021-01-01

32周总缓解率为24%,48周升至36%,最佳总缓解率达54%;估计36个月无进展生存率为73%,总生存率为85%。尽管主要终点未达到,但客观缓解和有利的无进展生存提示伊布替尼可能使这些患者获益。

要点

  • 伊布替尼在复发经典型或变异型毛细胞白血病中32周ORR为24%,最佳ORR为54%。
  • 估计36个月PFS为73%,OS为85%,提示可延长疾病控制。
  • 常见不良事件为腹泻、乏力、肌痛、恶心及血细胞减少,需关注毒性管理。

核心结论

  • 伊布替尼可安全用于毛细胞白血病患者并产生客观缓解,延长疾病控制。
  • 尽管主要终点未达到,但重度预处理患者的客观缓解和有利PFS提示潜在获益。

研究设计与样本

  • 患者接受两种剂量:24例420 mg,13例840 mg。
  • 主要终点为32周总缓解率,次要终点包括毒性、无进展生存和总生存。

主要发现

  • 32周ORR为24%,48周ORR为36%,最佳ORR为54%。
  • 中位随访3.5年(范围0-5.9年),估计36个月PFS为73%,OS为85%。
  • 最常见不良事件为腹泻(59%)、乏力(54%)、肌痛(54%)和恶心(51%)。
  • 血液学不良事件常见:贫血(43%)、血小板减少(41%)、中性粒细胞减少(35%)。

临床怎么用

  • 对于嘌呤类似物治疗无效的复发经典型或变异型毛细胞白血病患者,伊布替尼可作为可选治疗。
  • 治疗期间需监测腹泻、乏力、肌痛、恶心及血细胞减少等不良事件。

局限性

  • 主要终点(32周ORR)未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent targeting Bruton tyrosine kinase in the B-cell receptor signaling pathway, is highly effective in several malignancies. Its activity in HCL was unknown, so we conducted a multisite phase 2 study of oral ibrutinib in patients with either relapsed classic or variant hairy cell leukemia. The primary outcome measure was the overall response rate (ORR) at 32 weeks, and we also assessed response at 48 weeks and best response during treatment. Key secondary objectives were characterization of toxicity and determination of progression-free survival (PFS) and overall survival (OS). Thirty-seven patients were enrolled at 2 different doses (24 at 420 mg, 13 at 840 mg). The median duration of follow-up was 3.5 years (range, 0-5.9 years). The ORR at 32 weeks was 24%, which increased to 36% at 48 weeks. The best ORR was 54%. The estimated 36-month PFS was 73% and OS was 85%. The most frequent adverse events were diarrhea (59%), fatigue (54%), myalgia (54%), and nausea (51%). Hematologic adverse events were common: anemia (43%), thrombocytopenia (41%), and neutropenia (35%). Ibrutinib can be safely administered to patients with HCL with objective responses and results in prolonged disease control. Although the initial primary outcome objective of the study was not met, the observation of objective responses in heavily pretreated patients coupled with a favorable PFS suggests that ibrutinib may be beneficial in these patients. This trial was registered at www.clinicaltrials.gov as #NCT01841723.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rogers KA, Andritsos LA, Wei L, et al. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood. 2021. PMID: 33754642. doi:10.1182/blood.2020009688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。